2 completed, 1 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow etesevimab: new trials by email Literature Review of etesevimab trials Research Report on etesevimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19) JS016 - COVID-19, SARS-CoV-2 | Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2021-01-20 | 2021-10-21 |
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness LY3819253, LY3832479, LY3853113 - COVID-19 | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 3307 | 2020-06-17 | 2024-04-11 |
COVID-19 (3)
Eli Lilly and Company (2) · Peking Union Medical College Hospital (1)
United States (2) · Argentina (1) · China (1) · Puerto Rico (1)
Bin DU, Prof. (1)
PMID 35713300, PMID 34374951, PMID 34473343, PMID 33113295, PMID 33215063, PMID 33475701, PMID 34260849, PMID 34346827, PMID 34718468, PMID 35191746, PMID 35493124, PMID 37329415, PMID 38291279, PMID 39230829